The Overall Hospital-Treated MRSA Infections Drug Market Will Increase from $656 Million in 2010 to $730 Million in 2020, According to Findings from Decision Resources
BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, in 2020, Forest/AstraZeneca/Dainippon Sumitomo’s Teflaro and Trius Therapeutics’ tedizolid will capture nearly one-third of the market for hospital-treated Methicillin-resistant Staphylococcus aureus (MRSA) infections in key indications (nosocomial pneumonia, bloodstream infections, and complicated skin and skin structure/surgical site infections). Growth in the MRSA drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will be driven primarily by the uptake of Teflaro (which launched in the U.S. in January 2011) and tedizolid, a second-generation oxazolidinone in Phase III clinical trials for acute bacterial skin and skin-structure infections (ABSSSIs).
The Pharmacor advisory service entitled Methicillin-Resistant Staphylococcus Aureus, which will be published by the end of the month, finds that the overall hospital-treated MRSA infections drug market will increase from $656 million in 2010 to $730 million in 2020. The launch of Teflaro, a first-in-class broad-spectrum anti-MRSA cephalosporin, has expanded the MRSA armamentarium, which previously consisted of primarily narrow-spectrum agents targeted to MRSA. The diverse late-stage MRSA pipeline includes broad-spectrum agents such as quinolones—Rib-x/Sanofi’s delafloxacin and Furiex’s JNJ-Q2—and several narrow spectrum agents which will launch over the next decade, including tedizolid, Durata’s dalbavancin and The Medicines Company’s oritavancin. The availability of new broad- as well as narrow-spectrum agents will give physicians additional options and lines of therapy for the treatment of empiric and confirmed MRSA infections in the hospital.
The findings also reveal that continued uncertainty over guidelines from the U.S. Food and Drug Administration (FDA) for developing clinical trials in ABSSSIs and nosocomial pneumonia has contributed to the delay or discontinuation of clinical trials for several antibacterials. At issue are new early-response primary end points recommended by the FDA in ABSSSI trials that the Infectious Disease Society of America (IDSA) has deemed not clinically meaningful. Newly recommended inclusion and exclusion criteria in nosocomial pneumonia trials will likely lead to larger and more expensive trials.
“In addition, the IDSA considers the treatment effect and non-inferiority margins set by the FDA for both ABSSSI and nosocomial pneumonia trials to be excessively conservative,” said Decision Resources Analyst David Holman, Ph.D. “These changes have prompted several companies to delay or discontinue clinical trials in ABSSSI and have largely prevented companies from conducting trials for agents that treat nosocomial pneumonia.”
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Christopher Comfort, 781-993-2597
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Hospitals Pharmaceutical General Health